Summary
Introduction
PEndorphin applied locally to the nucleus tractus decrease in blood pressure and heart rate [ 1 I. The NTS is also a site of action of catecholamines and the centrally acting hypotensive agents clonidine and a-methyldopa 12-41. In conscious, spontaneously hypertensive rats (SHR), the decrease in blood pressure and heart rate produced by intravenous clonidine and a-methyldopa is reversed by naloxone [51, indicating that central a-receptor stimulation involves the activation of opiate receptors. Since naloxone and clonidine appear not to interact with the same receptor site, it was suggested that clonidine and ct-methyldopa induce the release of an endogenous opiate, which is involved in the central control of sympathetic tone [61. More recently it has been reported that clonidine and a-methylnoradrenaline, the latter an active metabolite of a-methyldopa, induce the release of a peptide with p-endorphin-like immunoreactivity from brain-stem slices of SHR, but not from their normotensive, genetically matched, WistarKyoto control rats [71. This response is specific for the active L isomer of a-methylnoradrenaline and is reduced by yohimbine. On the basis of these findings, it was speculated that the release of pendorphin-like material in the brain stem contributes to the antihypertensive action of central cr-receptor stimulants in the SHR 171. In this study a possible interaction between catecholamines and endorphins has been investigated in an experimental model of hypertension, and the NTS as a possible site of this effect has been examined.
Methods
Male Wistar rats (Cpb, TNO, Zeist, The Netherlands) were used. Renal hypertension was induced by the application of a solid silver clip (0.2 mm internal diameter) to the left renal artery of rats weighing 125-135 g (two kidney, one clip Goldblatt model) 181. The control group was subjected to the same operative procedure, but no clip was applied. The rats were used 3-4 weeks after operation, when under light ether anaesthesia a catheter was placed in a tail artery, tunnelled under the skin and exteriorized at the scruff of the neck. The animals were allowed several hours to recover from the effects of the anaesthesia, before drug administration and blood pressure recordings commenced. Arterial pressure and heart rate were recorded from the tail artery catheter by means of a Statham P23-AC gauge transducer and displayed on a Grass polygraph.
For direct application of drugs into the NTS, rats weighing 200-250 g were anaesthetized with urethane (1.4 g/kg). The rat was placed in a stereotactic head holder and the head fixed to an angle of 4 5 O downward. After exposure of the lower brain stem, unilateral micro-injections into the NTS were given through a glass cannula (outer diameter 60 p), in a volume of 0.4 pl, which was delivered in 10 s. After experimentation the correct position of the injection sites was confirmed by histology. Blood pressure and heart rate were measured directly from a carotid artery catheter.
The following drugs were used: (-)a-methyldopa, (f)a-methylnoradrenaline, naloxone, naltrexone, antiserum to Bendorphin, and control rabbit serum. All agents were dissolved in, or diluted with, sodium chloride solution (154 mmol/l: saline).
Results

Effect of (-)a-methyldopa in renal hypertensive rats
The basal mean blood pressure of the conscious renal hypertensive rats ranged from 180 to 230 mmHg. a-Methyldopa (100 mg/kg intraperitoneally) induced a gradual decrease in blood pressure, which reached a maximum at about 2.5 h after administration, when the change was -60 mmHg. An initial increase in heart rate occurred, which persisted until about 60-90 min after administration [31.
The opiate antagonist naltrexone (5 mg/kg subcutaneously) did not affect either the blood pressure or heart rate of the renal hypertensive rats. However, when it was administered 15 min before a-methyldopa, the decrease in blood pressure induced by the amine was both delayed and significantly (P < 0-05) attenuated from 2 h onwards (Fig. 1) . The changes in heart rate induced by a-methyldopa were not affected by naltrexone. o--a, saline + cr-methyldopa (100 mg/kg; n = 6); L@ naltrexone (5 mg/kg) + smethyldopa (100 mg/kg) (n = 5). The results are expressed as the means & SE, and were compared by using a Student's t-test for unpaired data.
Eflect of microinjection of (f)crmethylnoradrenaline into the NTS
The basal mean blood pressure and heart rate of the urethane-anaesthetized rats ranged from 90 to 120 mmHg and 400 to 430 beatshin. Upon administration into the NTS, a-methylnoradrenaline caused a dose-related fall in blood, pressure and heart rate. The fall in both blood pressure and heart rate were apparent immediately after injection. However, although the maximum change in blood pressure occurred after 10-15 min, the maximum decrease in heart rate did not occur until about 25 min, both gradually returning to control values. Naloxone (1 mg/kg subcutaneously), administered 15 min before a-methylnoradrenaline (50 nmol) into the NTS, attenuated the fall in blood pressure and reduced the bradycardia induced by the catecholamine. At the time of the maximum change in both blood pressure and heart rate these values were about 2 mmHg and -20 beatshin after naloxone and -25 mmHg and -50 beatshin after saline pretreatment respectively.
The local application of naloxone (1-1000 ng)
into the NTS did not affect blood pressure, but 1 ng administered 10 min before a-methylnoradrenaline (50 nmol) partially antagonized the fall in mean arterial pressure induced by the amine, being about -30 and -10 mmHg after saline and naloxone pretreatment respectively. This dose of naloxone was without effect on the Opiates and the hypotensive effects of a-methyldopa 295s bradycardia caused by a-methylnoradrenaline. However, a larger dose (10 ng) of the opiate receptor antagonist completely blocked both the fall in blood pressure and heart rate. Microinjection of antiserum to Pendorphin (1 :50 dilution) into the NTS, 10 min before smethylnoradrenaline (50 nmol), blocked the fall in blood pressure, being about -24 mmHg after pretreatment with normal rabbit serum and -5 mmHg after P-endorphin antiserum. Heart rate decrease was reduced.
Discussion
In this study the possible involvement of an opioid peptide in the antihypertensive effect resulting from central @receptor activation has been investigated. It has been reported that the antihypertensive action of clonidine and amethyldopa in SHR is mediated by a Fendorphin-like peptide, which is released by these centrally acting a-agonists [6, 71. Such an interaction also appears to be present in the renal hypertensive rat (two kidney, one clip Goldblatt model), since the -subcutaneous administration of naltrexone partially antagonized the fall in blood pressure induced by a-methyldopa, injected intraperitoneally. This interaction, however, appears to be absent in the normotensive pentobarbitone-anaesthetized rat 191, although in that publication [91 the authors assumed that all opioid peptides produce a blood pressure increase.
Microinjection of a-methylnoradrenaline into the NTS produced a rapid and marked fall in blood pressure, which was accompanied by bradycardia. Both the depressor response and fall in heart rate were naloxone-reversible, the opiate antagonist being administered subcutaneously or directly into the NTS. These findings suggest that the activation of a-receptors in the NTS by a-methylnoradrenaline, to induce a fall in mean blood pressure, requires the stimulation of opiate receptors.
Antiserum to P-endorphin blocked the depressor response and reduced the bradycardia resulting from a-methylnoradrenaline administration. It is possible that the catecholamine is releasing a P-endorphin-like peptide to cause the fall in blood pressure and heart rate. However, it seems improbable that the opioid peptide involved is D-endorphin, since although &endorphin produces a decrease in blood pressure and heart rate upon microinjection into the NTS, the time courses of these changes are much slower than those of amethylnoradrenaline [ I] . Perhaps a shorter fragment of P L P H is involved, with which the antiserum may cross-react.
In conclusion, it appears that a Pendorphinlike peptide is involved in the hypotensive effect resulting from central a-receptor stimulation. The NTS is a possible site of this action.
